Clinical Trials · NCT05259033
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 683
- Start date
- Apr 2022
- Locations
- 193 sites, 15 countries
- Primary endpoint
- Change From Baseline in Glycosylated Haemoglobin (HbA1c)